Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

References

• Zimmer P Alberti KG Shaw J Global and societal implications of the diabetes epidemic Nature 2001 414 782 787 11742409
   PubMed Web of Science ®Google Scholar
• Zimmet P Lefèbvre P The global NIDDM epidemic: treating the disease and ignoring the symptom [Editorial] Diabetologia 1996 39 1247 1248 8932987
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2009 Diabetes Care 2009 32 Suppl 1 S13 S61 19118286
   PubMed Web of Science ®Google Scholar
• The DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus N Engl J Med 1993 329 977 986 8366922
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HAW Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Saydah SH Fradkin J Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 2004 291 335 342 14734596
   PubMed Web of Science ®Google Scholar
• Kjems LL Holst JJ Vølund A Madsbad S The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects Diabetes 2003 52 380 386 12540611
   PubMed Web of Science ®Google Scholar
• Meier JJ Nauck MA Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 2008 4 606 607 18725906
   PubMedGoogle Scholar
• Vollmer K Holst JJ Baller B Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance Diabetes 2008 57 678 687 18057091
   PubMed Web of Science ®Google Scholar
• Vilsbøll T Krarup T Deacon CF Madsbad S Holst JJ Reduced post- prandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 2001 50 609 613 11246881
   PubMed Web of Science ®Google Scholar
• Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 1993 91 301 307 8423228
   PubMed Web of Science ®Google Scholar
• Meier JJ Nauck MA Kranz D Secretion, degradation and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects Diabetes 2004 53 654 662 14988249
   PubMed Web of Science ®Google Scholar
• Hansen L Deacon CF Orskov C Holst JJ Glucagon-like peptide-1- (7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyly peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 1999 140 5356 5363 10537167
   PubMed Web of Science ®Google Scholar
• Hupe-Sodmann K McGregor GP Bridenbaugh R Characterisation of the processing by human neutral endopeptidase 24.11 of GLP- 1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides Regul Pept 1995 58 149 156 8577927
   PubMed Web of Science ®Google Scholar
• Verspohl EJ Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors Pharmacol Ther 2009 124 113 138 19545590
   PubMed Web of Science ®Google Scholar
• Copley K McCowen K Hiles R Nielsen LL Young A Parkes DG Investigation of exenatide elimination and its in vivo and in vitro degradation Curr Drug Metab 2006 7 367 374 16724926
   PubMed Web of Science ®Google Scholar
• Thorens B Porret A Bühler L Deng SP Morel P Widmann C Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor Diabetes 1993 42 1678 1682 8405712
   PubMed Web of Science ®Google Scholar
• Brubaker PL Drucker DJ Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 2004 145 2653 2659 15044356
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Kim DD Fineman MS Baron AD for Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• Kim D MacConell L Zhuang D Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 2007 30 1487 1493 17353504
   PubMed Web of Science ®Google Scholar
• Drucker DJ Buse JB Taylor K for DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Bergenstal R Wysham C Yan P Macconell L Malloy J Porter L DURATION-2: exenatide once weekly demonstrated superior glycemic control and weight reduction compared to sitagliptin or pioglitazone after 26 weeks of treatment American Diabetes Association 2009 Scientific Sessions 2009 Jun 5–9 New Orleans, LA, USA Abstract 6-LB
   Google Scholar
• Zinman B Hoogwerf BJ Durán García S The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomised trial Ann Intern Med 2007 146 477 485 17404349
   PubMed Web of Science ®Google Scholar
• Bain SC Stephens JW Exenatide and pancreatitis: an update Expert Opin Drug Saf 2008 7 643 644 18983211
   PubMed Web of Science ®Google Scholar
• Noel RA Braun DK Patterson R Bloomgren G Estimated incidence of acute pancreatitis in patients with type 2 diabetes Pharmacol Drug Saf 2008 17 S1 S29
   PubMed Web of Science ®Google Scholar
• Weise WJ Sivanandy MS Block CA Comi RJ Exenatide-associated ischemic renal failure Diabetes Care 2009 32 e22 e23 19171732
   PubMedGoogle Scholar
• BYETTA (exenatide) injection prescribing information 2008
   Google Scholar
• Garbutt JC Kranzler HR O’Malley SS for Vivitrex Study Group Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomised controlled trial JAMA 2005 293 1617 1625 15811981
   PubMed Web of Science ®Google Scholar
• Klonoff DC Buse JB Nielsen LL Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 275 286 18053320
   PubMed Web of Science ®Google Scholar
• Best JH Boye KS Rubin RR Cao D Kim TH Peyrot M Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily Diabet Med 2009 26 7 722 728 19573122
   PubMed Web of Science ®Google Scholar
• Rubin RR Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus Am J Med 2005 118 Suppl 5A S27 34
   PubMed Web of Science ®Google Scholar
• Secnik Boye K Matza LS Oglesby A Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes Health Qual Life Outcomes 2006 4 80 17034640
   PubMed Web of Science ®Google Scholar
• Brändle M Erny-Albrecht KM Goodall G Spinas GA Streit P Valentine WJ Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with type 2 diabetes in Switzerland Int J Clin Pharmacol Ther 2009 47 501 515 19640359
   PubMed Web of Science ®Google Scholar
• Stein LL Dong MH Loomba R Insulin sensitisers in nonalcoholic fatty liver disease and steatohepatitis: current status Adv Ther 2009 26 893 907 19921118
   PubMed Web of Science ®Google Scholar
• Bulchandani D Nachnani J Eaton C Hamburg M Association of exenatide with liver enzymes in patients with type 2 diabetes Endocrinologist 2009 19 114 115
   Google Scholar
• Buse JB Klonoff DC Nielsen LL Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the openlabel, uncontrolled extension of three double-blind, placebo-controlled trials Clin Ther 2007 29 139 153 17379054
   PubMed Web of Science ®Google Scholar
• Aimaretti G Liraglutide: a once-daily human glucagon-like peptide-1 analogue J Endocrinol Invest 2009 32 701 703 19942822
   PubMed Web of Science ®Google Scholar
• Croom KF McCormack PL Liraglutide: a review of its use in type 2 diabetes mellitus Drugs 2009 69 1985 2004 19747013
   PubMed Web of Science ®Google Scholar
• Werner U Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010 Ann Endocrinol (Paris) 2008 69 164 165 18417092
   PubMed Web of Science ®Google Scholar
• Rosenstock J Reusch J Bush M Yang F Stewart M for Albiglutide Study Group Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing Diabetes Care 2009 32 1880 1886 19592625
   PubMed Web of Science ®Google Scholar
• Nauck MA Ratner RE Kapitza C Berria R Boldrin M Balena R Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study Diabetes Care 2009 32 1237 1243 19366970
   PubMed Web of Science ®Google Scholar